Tenapanor Hydrochloride Powder CAS 1234365-97-9

Tenapanor Hydrochloride（CAS 1234365-97-9）, is a first-in-class, minimally absorbed small-molecule NHE3 inhibitor API powder. It acts locally within the gastrointestinal tract by blocking sodium-hydrogen exchanger isoform 3, reducing intestinal sodium and phosphate absorption. This compound appears as white to off-white solid powder, with strict control over crystal form and residual impurities. Our product is synthesized via refined routes, delivering consistent purity and reliable batch uniformity. Minimal systemic absorption lowers systemic adverse effects, supporting its dual potential for irritable bowel syndrome with constipation and hyperphosphatemia in CKD dialysis patients. 

Each batch undergoes full HPLC, moisture and heavy metal testing before release. Complete raw material traceability is maintained throughout production. It serves as critical pharmaceutical raw material for formulation development, preclinical pharmacological studies and clinical trial material preparation for global drug research institutions and manufacturers.

1. API raw material for oral tablet formulations targeting irritable bowel syndrome with constipation (IBS-C).

2. Active pharmaceutical ingredient for drugs to reduce serum phosphorus in chronic kidney disease patients receiving dialysis.

3. Research compound for in vitro and in vivo pharmacological studies of intestinal NHE3 sodium/hydrogen exchanger mechanism.

4. Reference substance for analytical method validation and impurity analysis in gastrointestinal and renal drug development laboratories.

■ Every batch undergoes HPLC, moisture, impurity and appearance testing from raw materials to finished packaging.

■ Organic impurities, residual solvents and heavy metals conform to ICH standards.

■ Unique batch IDs track all production, testing and shipping records.

■ Low-temp, light & moisture resistant storage safeguards product stability.

■ Application consulting, spec interpretation and technical guidance available.